Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers


  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 47 articles:
HTML format

Single Articles

    November 2023
  1. NERO C, Bizzarri N, Di Berardino S, Sillano F, et al
    Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY).
    Eur J Cancer. 2023;196:113435.
    PubMed     Abstract available

    October 2023
  2. SAVOYE I, Silversmit G, Bourgeois J, De Gendt C, et al
    Association between hospital volume and outcomes in invasive ovarian cancer in Belgium: A population-based study.
    Eur J Cancer. 2023;195:113402.
    PubMed     Abstract available

  3. BIZZARRI N, Imterat M, Fruscio R, Giannarelli D, et al
    Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
    Eur J Cancer. 2023;195:113398.
    PubMed     Abstract available

  4. LEARY A, Oaknin A, Trigo JM, Moreno V, et al
    Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
    Eur J Cancer. 2023;192:113259.
    PubMed     Abstract available

    September 2023
  5. VERGOTE I, Matias-Guiu X
    New FIGO 2023 endometrial cancer staging validation. Welcome to the first molecular classifiers and new pathological variables!
    Eur J Cancer. 2023 Sep 27:113318. doi: 10.1016/j.ejca.2023.113318.

  6. WOJTYLA C, Bertuccio P, Giermaziak W, Santucci C, et al
    European trends in ovarian cancer mortality, 1990-2020 and predictions to 2025.
    Eur J Cancer. 2023;194:113350.
    PubMed     Abstract available

  7. MATSUO K, Klar M, Song BB, Roman LD, et al
    Validation of the 2023 FIGO staging schema for advanced endometrial cancer.
    Eur J Cancer. 2023 Sep 21:113316. doi: 10.1016/j.ejca.2023.113316.

  8. PETRELLI F, Cavallone M, Dottorini L
    10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis.
    Eur J Cancer. 2023;193:113322.
    PubMed     Abstract available

  9. SCHWAMEIS R, Fanfani F, Ebner C, Zimmermann N, et al
    Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.
    Eur J Cancer. 2023 Sep 1:113317. doi: 10.1016/j.ejca.2023.113317.
    PubMed     Abstract available

    August 2023
  10. DING S, Li H
    Re: A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
    Eur J Cancer. 2023 Aug 1:112978. doi: 10.1016/j.ejca.2023.112978.

    July 2023
  11. HOWROYD LR, Cornell I, Benson C, Napolitano A, et al
    Pseudoprogression in patients with uterine leiomyosarcoma treated with first-line single-agent doxorubicin.
    Eur J Cancer. 2023;192:113261.
    PubMed     Abstract available

  12. CORBAUX P, You B, Glasspool RM, Yanaihara N, et al
    Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
    Eur J Cancer. 2023;191:112966.
    PubMed     Abstract available

    June 2023
  13. VALENZA C, Trapani D, Gandini S, Sposetti C, et al
    Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
    Eur J Cancer. 2023;190:112944.
    PubMed     Abstract available

    May 2023
  14. GONZALEZ-MARTIN A, Pothuri B, Vergote I, Graybill W, et al
    Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
    Eur J Cancer. 2023 May 3:S0959-8049(23)00225-3. doi: 10.1016/j.ejca.2023.
    PubMed     Abstract available

    April 2023
  15. LOVERIX L, Vergote I, Busschaert P, Vanderstichele A, et al
    PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2023;188:131-139.
    PubMed     Abstract available

  16. PETERS ITA, Marchetti C, De Palma A, Giannarelli D, et al
    Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis.
    Eur J Cancer. 2023;187:77-86.
    PubMed     Abstract available

    March 2023
  17. LORUSSO D, Colombo N, Herraez AC, Santin AD, et al
    Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
    Eur J Cancer. 2023;186:172-184.
    PubMed     Abstract available

  18. PERRONE E, Capasso I, De Felice F, Giannarelli D, et al
    Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
    Eur J Cancer. 2023;186:98-112.
    PubMed     Abstract available

    February 2023
  19. WENZEL HHB, Hardie AN, Moncada-Torres A, Hogdall CK, et al
    A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
    Eur J Cancer. 2023;185:61-68.
    PubMed     Abstract available

  20. WANG J, Cai L, Song Y, Sun T, et al
    Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
    Eur J Cancer. 2023;184:73-82.
    PubMed     Abstract available

    January 2023
  21. HERZOG TJ, Vergote I, Gomella LG, Milenkova T, et al
    Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    Eur J Cancer. 2023;179:136-146.
    PubMed     Abstract available

    December 2022
  22. CUEVA JF, Palacio I, Churruca C, Herrero A, et al
    Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
    Eur J Cancer. 2022;182:3-14.
    PubMed     Abstract available

  23. PANOUTSOPOULOU K, Magkou P, Dreyer T, Dorn J, et al
    tRNA-derived small RNA 3'U-tRF(ValCAC) promotes tumour migration and early progression in ovarian cancer.
    Eur J Cancer. 2022;180:134-145.
    PubMed     Abstract available

  24. SABATIER R, Rousseau F, Joly F, Cropet C, et al
    Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged >/=65 years from the PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2022;181:42-52.
    PubMed     Abstract available

    September 2022
  25. XU B, Hu X, Li W, Sun T, et al
    Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
    Eur J Cancer. 2022;175:236-245.
    PubMed     Abstract available

  26. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
    Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Eur J Cancer. 2022;175:180-186.
    PubMed     Abstract available

  27. GONZALEZ-MARTIN A, Desauw C, Heitz F, Cropet C, et al
    Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2022;174:221-231.
    PubMed     Abstract available

    August 2022
  28. GOLDRAT O, De Cooman M, Mailliez A, Delbaere A, et al
    Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Eur J Cancer. 2022;174:134-141.
    PubMed     Abstract available

    July 2022
  29. OAKNIN A, Monk BJ, Vergote I, Cristina de Melo A, et al
    EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
    Eur J Cancer. 2022 Jul 31. pii: S0959-8049(22)00160.
    PubMed     Abstract available

  30. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    PubMed     Abstract available

  31. PASHANKAR F, Hanley K, Lockley M, Stoneham S, et al
    Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference.
    Eur J Cancer. 2022;173:59-70.
    PubMed     Abstract available

    June 2022
  32. PESENTI C, Beltrame L, Velle A, Fruscio R, et al
    Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.
    Eur J Cancer. 2022;171:85-95.
    PubMed     Abstract available

    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.

  34. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    PubMed     Abstract available

    May 2022
  35. SIMON S, Francis KE, Dalrymple JE, Gebski V, et al
    Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2022;170:169-178.
    PubMed     Abstract available

  36. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    PubMed     Abstract available

  37. PAULET L, Trecourt A, Leary A, Peron J, et al
    Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Eur J Cancer. 2022;166:87-99.
    PubMed     Abstract available

    April 2022
  38. AKESSON A, Adok C, Dahm-Kahler P
    Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy - A population-based cohort study.
    Eur J Cancer. 2022;169:54-63.
    PubMed     Abstract available

  39. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    PubMed     Abstract available

    March 2022
  40. CARTER TJ, George C, Harwood C, Nathan P, et al
    Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease.
    Eur J Cancer. 2022;166:240-253.
    PubMed     Abstract available

    December 2021
  41. DITTO A, De Cecco L, Paolini B, Alberti P, et al
    Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
    Eur J Cancer. 2021;161:55-63.
    PubMed     Abstract available

  42. JIANG F, Lin JK, Xiang Y, Xu ZF, et al
    The impact of pulmonary metastases on therapeutic response and prognosis in malignant gestational trophoblastic neoplasia patients: a retrospective cohort study.
    Eur J Cancer. 2021 Dec 13. pii: S0959-8049(21)01212.
    PubMed     Abstract available

    October 2021
  43. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
    The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.
    Eur J Cancer. 2021;158:111-122.
    PubMed     Abstract available

    September 2021
  44. VERGOTE I, Ray-Coquard I, Anderson DM, Cantuaria G, et al
    Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Eur J Cancer. 2021;157:415-423.
    PubMed     Abstract available

  45. KANTIDAKIS G, Litiere S, Neven A, Vinches M, et al
    Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sar
    Eur J Cancer. 2021;154:253-268.
    PubMed     Abstract available

  46. HOVEN E, Fagerkvist K, Jahnukainen K, Ljungman L, et al
    Sexual dysfunction in young adult survivors of childhood cancer - A population-based study.
    Eur J Cancer. 2021;154:147-156.
    PubMed     Abstract available

    March 2021
  47. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.